Contact
searchSearch
HMP Global

News

Radiation Protection Systems
Rampart IC Secures Series B Financing to Fuel Strategic Growth and Expand Access to Radiation Safety Solutions
04/24/2025
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Rampart IC, a medical technology...
04/24/2025
Cath Lab Digest
MEeting Update
SCAI Scientific Sessions 2025 Features Latest Clinical Innovations in Cardiology Care
04/24/2025
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.  
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.  
Whether you’re focused on...
04/24/2025
Cath Lab Digest
Scientific Statement
HRS and ACC Release Joint Scientific Statement on the Safety of Same-Day Discharge for Intracardiac Catheter Ablation Procedures
04/24/2025
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
This document draws on global...
04/24/2025
EP Lab Digest
(Reproduced with permission from NEJM AI, Lampert, 2025. Copyright 2025 Massachusetts Medical Society)
AI: HCM
AI Algorithm Can Help Identify High-Risk Heart Patients to Quickly Diagnose, Expedite, and Improve Care
04/24/2025
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
Using the model to analyze...
04/24/2025
Cath Lab Digest
News
The Heart Rhythm Society Announces Framework for Establishing Atrial Fibrillation Centers of Excellence and Key Operational Standards
04/23/2025
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
The Heart Rhythm Society (HRS)...
04/23/2025
EP Lab Digest
Peripheral Arterial Disease
Efemoral Medical Releases Positive Long-Term Results from EFEMORAL I
04/23/2025
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human...
04/23/2025
Cath Lab Digest
Large-Bore Vascular Closure
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
04/22/2025
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The PerQseal® Elite vascular...
04/22/2025
Cath Lab Digest
Lower-extremity intervention
First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using R3 Vascular's Magnitude Drug-Eluting Bioresorbable Scaffold
04/22/2025
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its...
04/22/2025
Cath Lab Digest
Uncontrolled Hypertension
Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation (AVIM) Therapy.
04/22/2025
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
“Patients at higher risk for...
04/22/2025
Cath Lab Digest
Cardiomyopathy
FDA Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
04/21/2025
Camzyos is an FDA-approved cardiac myosin inhibitor for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.(1)
Camzyos is an FDA-approved cardiac myosin inhibitor for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.(1)
Camzyos is an FDA-approved...
04/21/2025
Cath Lab Digest

News

Radiation Protection Systems
Rampart IC Secures Series B Financing to Fuel Strategic Growth and Expand Access to Radiation Safety Solutions
04/24/2025
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Rampart IC, a medical technology...
04/24/2025
Cath Lab Digest
MEeting Update
SCAI Scientific Sessions 2025 Features Latest Clinical Innovations in Cardiology Care
04/24/2025
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.  
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.  
Whether you’re focused on...
04/24/2025
Cath Lab Digest
Scientific Statement
HRS and ACC Release Joint Scientific Statement on the Safety of Same-Day Discharge for Intracardiac Catheter Ablation Procedures
04/24/2025
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
This document draws on global...
04/24/2025
EP Lab Digest
(Reproduced with permission from NEJM AI, Lampert, 2025. Copyright 2025 Massachusetts Medical Society)
AI: HCM
AI Algorithm Can Help Identify High-Risk Heart Patients to Quickly Diagnose, Expedite, and Improve Care
04/24/2025
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
Using the model to analyze...
04/24/2025
Cath Lab Digest
News
The Heart Rhythm Society Announces Framework for Establishing Atrial Fibrillation Centers of Excellence and Key Operational Standards
04/23/2025
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
The Heart Rhythm Society (HRS)...
04/23/2025
EP Lab Digest
Peripheral Arterial Disease
Efemoral Medical Releases Positive Long-Term Results from EFEMORAL I
04/23/2025
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human...
04/23/2025
Cath Lab Digest
Large-Bore Vascular Closure
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
04/22/2025
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The PerQseal® Elite vascular...
04/22/2025
Cath Lab Digest
Lower-extremity intervention
First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using R3 Vascular's Magnitude Drug-Eluting Bioresorbable Scaffold
04/22/2025
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its...
04/22/2025
Cath Lab Digest
Uncontrolled Hypertension
Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation (AVIM) Therapy.
04/22/2025
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
“Patients at higher risk for...
04/22/2025
Cath Lab Digest
Cardiomyopathy
FDA Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
04/21/2025
Camzyos is an FDA-approved cardiac myosin inhibitor for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.(1)
Camzyos is an FDA-approved cardiac myosin inhibitor for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.(1)
Camzyos is an FDA-approved...
04/21/2025
Cath Lab Digest

Radiation Protection Systems
Rampart IC Secures Series B Financing to Fuel Strategic Growth and Expand Access to Radiation Safety Solutions
04/24/2025
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Rampart IC, a medical technology company developing market-leading radiation safety and orthopedic protection solutions for the interventional suite, announced the successful completion of its $21.6M Series B financing round. The round was...
Rampart IC, a medical technology...
04/24/2025
Cath Lab Digest
MEeting Update
SCAI Scientific Sessions 2025 Features Latest Clinical Innovations in Cardiology Care
04/24/2025
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.  
Whether you’re focused on clinical care, innovation, or training the next generation, there’s something here to support your clinical, research, and career goals,” said SCAI President James B. Hermiller, MD, MSCAI.  
Whether you’re focused on...
04/24/2025
Cath Lab Digest
Scientific Statement
HRS and ACC Release Joint Scientific Statement on the Safety of Same-Day Discharge for Intracardiac Catheter Ablation Procedures
04/24/2025
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
This document draws on global clinical data and real-world evidence to evaluate the impact of a cardiac ablation SDD strategy on patient safety, access, operational efficiencies, and healthcare costs. It also outlines best practices based on...
This document draws on global...
04/24/2025
EP Lab Digest
Heart Disease Research
Link Between Heart Attack Severity and Circadian Rhythm Unveiled by UTHealth Houston Researchers
04/24/2025
“If you have a heart attack in the morning, you are more likely to have fatal arrhythmias, heart failure, and you’re more likely to die from it. The question we asked is ‘Why?’” said Holger Eltzschig, MD, PhD.
“If you have a heart attack in the morning, you are more likely to have fatal arrhythmias, heart failure, and you’re more likely to die from it. The question we asked is ‘Why?’” said Holger Eltzschig, MD, PhD.
“If you have a heart attack in...
04/24/2025
Cath Lab Digest
(Reproduced with permission from NEJM AI, Lampert, 2025. Copyright 2025 Massachusetts Medical Society)
AI: HCM
AI Algorithm Can Help Identify High-Risk Heart Patients to Quickly Diagnose, Expedite, and Improve Care
04/24/2025
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
Using the model to analyze patients’ ECG results could allow cardiologists to prioritize the highest-risk patients to bring them in sooner for an appointment and treatment before symptoms begin or exacerbate.
Using the model to analyze...
04/24/2025
Cath Lab Digest
News
The Heart Rhythm Society Announces Framework for Establishing Atrial Fibrillation Centers of Excellence and Key Operational Standards
04/23/2025
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
The Heart Rhythm Society (HRS) releases a framework outlining criteria for establishing an Atrial Fibrillation (AF) Center of Excellence (CoE) and key operational standards to provide multidisciplinary care for AF patients.
The Heart Rhythm Society (HRS)...
04/23/2025
EP Lab Digest
Peripheral Arterial Disease
Efemoral Medical Releases Positive Long-Term Results from EFEMORAL I
04/23/2025
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human clinical trial evaluating the performance of the Efemoral Vascular Scaffold System (EVSS) for the treatment of patients suffering symptomatic peripheral arterial occlusive disease from atherosclerosis of the...
EFEMORAL I is a first-in-human...
04/23/2025
Cath Lab Digest
Large-Bore Vascular Closure
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
04/22/2025
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The PerQseal® Elite vascular closure system is a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer.
The PerQseal® Elite vascular...
04/22/2025
Cath Lab Digest
Lower-extremity intervention
First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using R3 Vascular's Magnitude Drug-Eluting Bioresorbable Scaffold
04/22/2025
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its...
04/22/2025
Cath Lab Digest
Uncontrolled Hypertension
Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation (AVIM) Therapy.
04/22/2025
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
“Patients at higher risk for mortality and morbidity associated with high blood pressure are the core of the population we are actively enrolling in the BACKBEAT global pivotal study of hypertensive pacemaker-indicated patients in...
“Patients at higher risk for...
04/22/2025
Cath Lab Digest

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use